Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
Author:
Publisher
Springer Science and Business Media LLC
Link
http://link.springer.com/content/pdf/10.1186/s13058-018-1050-7.pdf
Reference26 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.2.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed 23 June 23, 2017. To view the most recent and complete version of the guidelines, go online to NCCN.org .
3. Reinert T, Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol. 2015;7:304–20.
4. Murphy CG, Dickler MN. Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. Endocr Relat Cancer. 2016;23:R337–52.
5. Reinert T, Barrios CH. Definition of first-line endocrine therapy for hormone receptor-positive advanced breast cancer. J Clin Oncol. 2016;34:1959–60.
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Moderate adverse events and regional differences in CDK4/6 inhibitor treatment combined with palliative radiotherapy;Radiotherapy and Oncology;2023-11
2. Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice;Biotechnology & Biotechnological Equipment;2023-10-19
3. A review of FDA approved drugs and their formulations for the treatment of breast cancer;Frontiers in Pharmacology;2023-07-28
4. How I treat endocrine-dependent metastatic breast cancer;ESMO Open;2023-04
5. CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis;Therapeutic potential of Cell Cycle Kinases in Breast Cancer;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3